The Intracellular Proteome as a Source for Novel Targets in CAR-T and T-Cell Engagers-Based Immunotherapy

• Published in: Cells (Basel, Switzerland) Vol. 12; no. 1; p. 27
• Main Authors: Arman, Inbar, Haus-Cohen, Maya, Reiter, Yoram
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 21-12-2022; MDPI
• Subjects: Amino acids; Analysis; Antibodies; Antibodies - metabolism; Antigens; Cancer; Cancer immunotherapy; Cell surface; chimeric antigen receptor; Clinical trials; Cloning; Cytotoxicity; E coli; Glycoprotein gp100; Histocompatibility antigen HLA; Humans; Immunity; Immunotherapy; Immunotoxins; Intracellular; Lymphocytes; Lymphocytes T; Major histocompatibility complex; Melanoma; Melanoma - metabolism; Metastases; MHC; Patient outcomes; peptide; Peptides; Peptides - metabolism; Proteins; Proteome - metabolism; Proteomes; Proteomics; Receptors, Antigen, T-Cell - metabolism; Receptors, Chimeric Antigen - metabolism; Review; T cell receptor mimic; T cell receptors; T-cell-receptor-like antibodies; T-Lymphocytes; Israel; T cell receptor mimic; MHC; peptide; chimeric antigen receptor; T-cell-receptor-like antibodies
• ISSN: 2073-4409; 2073-4409
• DOI: 10.3390/cells12010027

The impressive clinical success of cancer immunotherapy has motivated the continued search for new targets that may serve to guide potent effector functions in an attempt to efficiently kill malignant cells. The intracellular proteome is an interesting source for such new targets, such as neo-antigens and others, with growing interest in their application for cell-based immunotherapies. These intracellular-derived targets are peptides presented by MHC class I molecules on the cell surface of malignant cells. These disease-specific class I HLA-peptide complexes can be targeted by specific TCRs or by antibodies that mimic TCR-specificity, termed TCR-like (TCRL) antibodies. Adoptive cell transfer of TCR engineered T cells and T-cell-receptor-like based CAR-T cells, targeted against a peptide-MHC of interest, are currently tested as cancer therapeutic agents in pre-clinical and clinical trials, along with soluble TCR- and TCRL-based agents, such as immunotoxins and bi-specific T cell engagers. Targeting the intracellular proteome using TCRL- and TCR-based molecules shows promising results in cancer immunotherapy, as exemplified by the success of the anti-gp100/HLA-A2 TCR-based T cell engager, recently approved by the FDA for the treatment of unresectable or metastatic uveal melanoma. This review is focused on the selection and isolation processes of TCR- and TCRL-based targeting moieties, with a spotlight on pre-clinical and clinical studies, examining peptide-MHC targeting agents in cancer immunotherapy.